Multiply Labs, Inc.
StreetZero Signal 72
About Multiply Labs, Inc.
Multiply Labs, Inc. develops robotic automation equipment and technology for drug manufacturing, focusing on precision medicines and automated production lines for cell and gene therapies. The San Francisco-based company aims to reduce manual processes in pharmaceutical manufacturing through innovative robotics and hardware. It has raised funding across multiple rounds with participation from institutional investors.
LATEST FUNDINGPrivate Placement
$52.3M
Announced 2026-11-05
TOTAL RAISED$116M
IN THE NEWS
- 🔗 Multiply Labs - Products, Competitors, Financials, Employees, Headquarters Locations
- 🔗 Multiply Labs - 2026 Company Profile, Team, Funding & Competitors - Tracxn
- 🔗 Multiply Labs, Inc.
- 🔗 Multiply Labs Raises USD75M in Series B Funding
- 🔗 Multiply Labs 2026 Company Profile: Valuation, Funding & Investors | PitchBook
EMPLOYEES—
FOUNDED2016
HQSan Francisco, CA, United States
Industry
Other Technology
Tags
RoboticsBiomanufacturingPharma Automation
Investors
Key highlights
- Raised $75M Series B in October 2026 led by NantWorks to scale automated cell and gene therapy production.
- Total funding reaches $111M-$116M across 8 rounds with 24 institutional investors.
- Backers include AstraZeneca, Teradyne, and biotech-focused funds validating robotics in pharma manufacturing.
- Company focuses on reducing manual labor in drug production via precision robotic systems.
Ask StreetZero about Multiply Labs, Inc.
Put our AI to work on this deal.
Similar companies
Other Other Technology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account